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Abstract Next generation sequencing technology is increas-
ingly utilized in oncology with the goal of targeting therapeu-
tics to improve response and reduce side effects. Interpretation
of tumor mutations requires sequencing of paired germline
DNA, raising questions about incidental germline findings.
We describe our experiences as part of a research team
implementing a protocol for whole genome sequencing
(WGS) of tumors and paired germline DNA known as the
Michigan Oncology Sequencing project (MI-ONCOSEQ)
that includes options for receiving incidental germline find-
ings. Genetic counselors (GCs) discuss options for return of
results with patients during the informed consent process and
document family histories. GCs also review germline findings
and actively participate in the multi-disciplinary Precision
Medicine Tumor Board (PMTB), providing clinical context
for interpretation of germline results and making recommen-
dations about disclosure of germline findings. GCs have en-
countered ethical and counseling challenges with participants,
described here. Although GCs have not been traditionally
involved in molecular testing of tumors, our experiences with
MI-ONCOSEQ demonstrate that GCs have important appli-
cable skills to contribute to multi-disciplinary care teams
implementing precision oncology. Broader use of WGS in
oncology treatment decision making and American College
of Medical Genetics and Genomics (ACMG) recommenda-
tions for active interrogation of germline tissue in tumor-
normal dyads suggests that GCs will have future opportunities
in this area outside of research settings.
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Background
Advances in tumor biology and cancer genomics have led to a
new era in cancer diagnosis and treatment, with identification
of somatic mutations within tumors leading to greater poten-
tial for targeted treatment based on genomic mutational pro-
files. This approach is not entirely novel but has historically
involved testing for specific somatic mutations dictated by
cancer location or pathology (Dancey et al. 2012) .
Increasing availability and decreasing costs of next generation
sequencing technology are expanding the potential for wide-
spread use of whole genome sequencing (WGS) of tumors as
opposed to targeted mutational testing or panel testing.
Genome wide mutational analysis of tumor tissue requires
parallel investigation of germline DNA in order to identify
tumor specific mutations. Identification of germline mutations
is secondary to the main purpose of this testing, generating
discussion and debate about how results of parallel germline
analysis should be addressed. The recently released American
College of Medical Genetics and Genomics (ACMG) recom-
mendations outline a minimum gene list for active interroga-
tion and disclosure when clinical sequencing occurs on
germline DNA, including the normal sample of a tumor-
normal sequenced dyad (Green et al. 2013). Clinical genetic
counselors (GCs) have not traditionally been involved in the
process of somatic tumor analysis, but reports of actionable
secondary germline findings within cancer predisposition
genes (Johnston et al. 2012), in addition to the ACMG rec-
ommendations, suggest a role for the clinical cancer GC.
The Michigan Oncology Sequencing Project (MI-
ONCOSEQ) is one initiative utilizingWGS to identify somat-
ic mutations in tumors in an attempt to develop biomarker
driven personalized oncology care. The project began in 2011
and was funded by the National Human Genome Research
Institute (NHGRI) and National Cancer Institute (NCI) as a
Clinical Sequencing Exploratory Research (CSER) project in
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July 2013 to study the challenges of utilizing genomic se-
quence data in routine clinical care. As one of three CSER
sites studying targeted oncology, MI-ONCOSEQ began with
the following goals (Roychowdhury et al. 2011):
1) To appropriately identify patients who could benefit from
biomarker driven oncology protocols
2) To develop an adequate informed consent process that
addresses the possibility of incidental germline findings
3) To implement an efficient pipeline for analysis
4) To identify which results should be disclosed to patients
5) To complete the analysis in a clinically relevant timeline
while remaining cost effective
From protocol development through project initiation, GCs
have made important contributions to addressing these study
goals and have become an integral strength to the MI-
ONCOSEQ program. Here we present several functions
GCs perform as part of the multi-disciplinary MI-
ONCOSEQ team, representing largely traditional GC roles
adapted to a new application. Our experiences highlight that
cancer GCs can utilize existing skills to enhance patient care
in the personalized oncology setting.
MI-ONCOSEQ Experience and Genetic Counselor Roles
Patient Population: Unique Aspects and Informed Consent
MI-ONCOSEQ initially enrolled adult patients, adding a sep-
arate pediatric protocol (PEDS-ONCOSEQ) in 2012. Both
protocols have been approved by the University of Michigan
Institutional Review Board. Patients with advanced cancer
considering Phase I clinical trials are eligible for participation,
with the goal of selecting individuals in whom standard of
care therapies have been insufficient or non-existent, reducing
the potential for undue study-related harm.
Patients considering phase I oncology trials represent a
unique population. While they do not meet established criteria
for vulnerable populations based on demographic and health
status characteristics (Seidenfeld et al. 2008), the presence of a
serious illness may create vulnerability (Nickel 2006). Phase I
trial participants are strongly motivated by hope of therapeutic
benefit (Catt et al. 2011; Daugherty et al. 1995) raising con-
cern regarding how they understand and weigh risks and
benefits of enrollment.
Pediatric patients are a vulnerable research population sub-
ject to additional protections (“Basic HHS Policy for
Protection of Human Research Subjects” 2009). The PEDS-
ONCOSEQ project mandates that tumor tissue from partici-
pants must be obtained during a standard of care biopsy or
resection, whereas adult participants must consent to a re-
search specific biopsy. Pediatric participants and their parents
can be viewed as having “nothing to lose” by enrolling, in that
there are no additional invasive medical procedures required
for participation. Thus perceived benefits may be weighed
against little to no perceived risk. Discussion of research
participation in pediatric populations is also complicated by
inclusion of parents and children together in the consent
process (Tait et al. 2003), an issue highlighted in our case
vignettes.
MI-ONCOSEQ, as a CSER site, includes a study arm
focused on ethics and health communication. This group,
comprised of bioethicists and health communications experts
with input from GCs, worked to develop and pilot the flexible
default consent. In developing the informed consent docu-
ment, the team considered that patients in these populations,
dealing with advanced cancer or a child with a serious illness,
might prefer to focus on results directly relevant to care of
their disease. This led to a provisional consent model with a
flexible default option for incidental findings not relevant to
treatment decisions for the current cancer. Default options
influence patients’ decisions in favor of the clinically pre-
ferred outcome without restricting their ability to make a
different choice, aiming for a balance between best clinical
judgment and respect for patient preference when possible
(Halpern et al. 2007). The default position is to disclose
incidental, actionable germline findings (further described
below). However, participants can opt out of receiving inci-
dental germline findings without direct impact on cancer
treatment in two categories: 1) results that may have signifi-
cance for biological family members; 2) results with potential
medical impact for the participant. As part of the recent CSER
funded work, the study team will monitor utility of the
existing document and make recommendations for modifica-
tions based on experience and outcomes of patient panels,
deliberative interviews, and input from other study team
members and referring oncologists.
Initial Study Visit
Potential MI-ONCOSEQ participants are identified and re-
ferred by the treating physician, typically an oncologist. All
participants meet with a study clinician (oncologist), study
coordinator and GC as part of their initial study visit. The
study clinician and study coordinator discuss the process and
purpose of tumor genome sequencing to identify biomarker
driven therapies, and collect samples for germline DNA anal-
ysis. The GC obtains a four generation cancer focused pedi-
gree, and explains that this information is used to help inter-
pret study findings. The GC discusses the difference between
tumor and germline sequencing, a distinction that has proven
to be confusing to patients undergoing tumor testing in other
studies (Richman et al. 2011; Pellegrini et al. 2012), and the
reasons why germline sequencing is important to the larger
study goal of identifying therapeutic targets. This leads to
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discussion of the possibility of incidental germline findings,
with the GC reviewing the options for receiving incidental
germline findings, answering participant questions, and
eliciting their preferences for information.
Review of Germline Variants, Precision Medicine Tumor
Board, and Follow Up
In the context of the MI-ONCOSEQ projects, incidental
germline findings are those identified as part of the study
protocol, which involves routine annotation of germline var-
iants in a list of 160 genes in recognized cancer pathways,
including all cancer-related genes recently recommended for
disclosure by the ACMG (Green et al. 2013), selected by the
bioinformatics team with input from GCs. GCs worked with
the bioinformatics team to set parameters for variant calls,
including a threshold of 2 % or less minor allele frequency in
the 1000 Genomes Project, chosen to allow identification of
polymorphic variants with potential clinical impact (e.g.
CHEK2 c.1100delC). Pedigrees and GC interpretation and
clinical comments are entered into a shared data portal avail-
able to the bioinformatics team. This information is used by
the bioinformatics team to help direct attention to potential
genes of interest. For example, a family history suggestive of
Lynch syndrome in a patient with a large number of somatic
variants in the tumor suggests possible germline mismatch
repair mutation and helps bioinformaticians target their
analysis.
GCs and a molecular geneticist review the assayed
germline findings in the context of medical and family history,
and research publicly available mutation databases and pri-
mary literature for relevant clinical information and pathogen-
ic classification. All variants with direct impact on treatment
decisions for the existing cancer are recommended for disclo-
sure, including any germline findings relevant to cancer path-
ways that may provide rationale for an existing therapeutic
option or clinical trial. Incidental germline variants not rele-
vant to treatment are divided into three groups based on
categories suggested by Berg et al. (Berg et al. 2013):
1) Known pathogenic variants associated with highly pene-
trant autosomal dominant conditions with clearly defined
medical management (e.g. BRCA1/BRCA2, Lynch syn-
drome genes) are all recommended for disclosure.
Mutations in this category could be relevant to either or
both default consent options, e.g. deleterious mutation in
BRCA1 with corresponding loss of heterozygosity in a
tumor would have relevance for biological family mem-
bers, and potential relevance for treatment (poly ADP
ribose polymerase (PARP) inhibitor trials).
2) Variants associated with moderate increases in cancer risk
with no clearly defined medical management established
(e.g. APC I1307K, CHEK2 1100delC); disclosure
decisions for these variants are made on a case by case
basis given frequent changes in available literature and
risk information. These variants are discussed as part of
PMTB deliberation in the context of family history.
Category 2 variants potentially relevant to cancer treat-
ment are all disclosed.
3) Heterozygous variants associated with autosomal reces-
sive conditions not requiring modification of medical
management (e.g. SLC26A4, the gene for autosomal re-
cessive Pendred syndrome, also important in thyroid tu-
morigenesis) are not routinely disclosed, unless this in-
formation is relevant to establishing a potential therapeu-
tic target.
As analysis of germline data becomes more efficient and
knowledge regarding implications of variants expands, rec-
ommendations for results reporting will undoubtedly change.
Many Category 2 genes are now part of clinically available
multi-gene panels, and more of these results will likely meet
our threshold for disclosure as clinical information
accumulates.
GCs attend the Precision Medicine Tumor Board (PMTB),
where all potentially actionable tumor and germline sequenc-
ing results are discussed by the entire multi-disciplinary team.
The PMTB was created specifically to manage both somatic
and germline results generated from tumor sequencing, to
deliberate on clinical implications of results for treatment
planning or clinical trial options, and to make recommenda-
tions about disclosure of findings. The team includes repre-
sentation from oncology, molecular genetics, clinical genetics,
pathology, bioinformatics, bioethics, and the phase I clinical
trial team. GCs present the pedigree information and highlight
any red flags for possible hereditary risk as well as the out-
comes of any known previous clinical genetic evaluation or
testing. A summary of the pertinent pedigree information is
included in the report to the referring clinician, along with any
identified red flags for hereditary cancer and availability of
clinical genetic counseling and testing. GCs discuss germline
findings of interest and present relevant data to aid in deliber-
ations. GCs also make recommendations about disclosure of
germline findings as part of the clinical genetics team. For
germline results recommended for disclosure, GCs provide
written documentation briefly describing the germline finding
and clinical implications for inclusion in the research results
report. After germline findings are reported, GCs work with
the referring oncologist to determine appropriate clinical fol-
low up for the patient depending on the situation. Clinical
genetic counseling is offered to all patients with reported
germline findings. The initial disclosure of germline findings
may be done by the referring oncologist or by GCs, depending
on physician preference and circumstances. Outcomes includ-
ing clinical genetic counseling visits, clinical confirmation of
germline findings, and testing completed in family members
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are being tracked. Follow up surveys to further explore patient
understanding and outcomes, as well as referring physicians
preferences and needs, are currently in development with the
ethics and health communications project team.
Early Findings of Interest
From project initiation in 2011 through April 30, 2013, 167
patients from 164 independent families consented to partici-
pate in MI-ONCOSEQ. Five participants (3 %) declined all
germline findings; 1 (0.6 %) declined germline results with
relevance to biological family members. Thirty-four patients
from 34 independent families have enrolled in PEDS-
ONCOSEQ; 4 (11.8 %) have declined all germline findings.
The remaining patients all agreed to receive germline findings.
Four generation pedigrees were collected for 162/164 adult
families (165/167 adult patients) and all 34 enrolled pediatric
patients. The first two enrolled adult patients did not provide
family history information; one family includes four adult
siblings all enrolled in the study. Fifty-seven of 162 (35.1 %)
adult participants’ pedigrees had one or more red flags for
hereditary cancer (Table 1); 22/57 (38.6 %) had prior genetic
counseling and/or genetic testing in themselves or a family
member. Seven (20.6 %) of 34 pediatric participants had one
or more red flags for hereditary cancer identified in the ped-
igree; 6/7 (85.7 %) had prior genetic counseling and/or genetic
testing in themselves or a family member. Pedigrees for pa-
tients previously seen for genetic counseling in the University
of Michigan Cancer Genetics Clinic (UMCGC) were
reviewed and updated; full pedigrees were obtained for pa-
tients who had prior genetic counseling outside the UMCGC.
Between January 1, 2013 and April 30, 2013, germline
analysis of a panel of 160 pre-selected cancer specific genes
was completed in 36 adult and 10 pediatric participants.
Approximately 312 single nucleotide germline variants with
a frequency of 2 % or less in the 1000 Genomes Project were
identified, an average of 6.8 variants per participant. Five
variants (5/312; 1.6 %) in 5 independent patients (5/46;
10.9 %) met the Category 1 or 2 thresholds for recommended
disclosure. Two of the five patients did not have any personal
or family history of cancer associated with the identified
variant.
Case Vignettes—Ethical and Counseling Issues
Ethical and counseling issues encountered since initiation of
MI-ONCOSEQ highlight the importance and applicability of
genetic counseling skills in this setting. The following vi-
gnettes outline a few such challenges that will likely occur
with increasing frequency in the clinical setting as well.
Pediatric Participants and Discordant Desires
Regarding Return of Germline Findings
Two PEDS-ONCOSEQ participants of assenting age (10–17)
disagreed with their parents/legal guardians about disclosure
of germline findings. Participant A was adopted and had no
information on biological family members. He was accompa-
nied to the study visit by his adoptive mother and two of her
relatives. When asked about preference for receiving action-
able incidental germline findings, the minor participant did
not wish to be notified. However, his adoptivemother request-
ed the information. The GC asked the participant if he would
allow his mother to learn the information about incidental
germline findings and he agreed, but again stated that he did
not want to know the information himself. No actionable
germline variants were identified.
Participant B was accompanied by his parents for initial
study visit. During the consent process, he expressed interest
in learning about actionable incidental germline findings,
while his parents were not interested. The GC established that
the participant was interested primarily out of curiosity, while
his parents wanted to focus on coping with his existing illness.
After further discussion, the participant was comfortable with
his parents’ desire to opt out of germline results. The partic-
ipant died 2 months after enrollment; germline analysis was
not completed prior to his death.
The final decision for return of optional incidental findings
in pediatric participants of assenting age (10–17 years) legally
rests with the consenting parent/legal guardian. In cases where
there is disagreement, GCs have the skills and training to
engage families in discussion of the risks, benefits and limi-
tations of testing and facilitate decision making that recog-
nizes and respects all of the parties involved, including the
assenting minor when appropriate. Professional guidelines
discourage testing of minors for adult onset conditions
(Mazoyer et al. 1996; “Points to consider: ethical, legal, and
psychosocial implications of genetic testing in children and
adolescents. American Society of Human Genetics Board of
Directors, American College of Medical Genetics Board of
Directors” 1995), although the ACMG recommends
Table 1 Red flags for hereditary cancer
- Earlier than average age at cancer diagnosis
- Rare or unusual tumor type with known association to inherited
syndrome
- Multiple primary cancers
- Two or more family members with the same or related cancers in same
lineage
- Ashkenazi Jewish ancestry with personal or family history of breast,
ovarian, prostate, or pancreatic cancer
Adapted from National Cancer Institute http://www.cancer.gov/
cancertopics/factsheet/Risk/genetic-testing
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reconsidering this approach as WGS becomes more common
(Green et al. 2013). The ethical arguments for and against
predictive testing in minors are extensive and well document-
ed, but they have generally failed to consider developmental
differences between adolescents and younger children and are
backed by little to no supporting data (Mand et al. 2012).
These arguments have also focused on testing for conditions
known to exist in the family, rather than disclosing mutations
identified through WGS. Our case examples highlight an area
for further research. The pediatric study was designed with the
parent/legal guardian as the final decision maker, but these
examples indicate that further research should investigate
alternative options that protect the interests of parents/legal
guardians and the future interests of minors.
Known Hereditary Risk in a Family who Declined Clinical
Genetic Counseling/Testing
A second dilemma faced by GCs participating in the initial
research visit was establishing a boundary between clinical
and research roles. GCs obtain a cancer focused pedigree for
research purposes to help with interpretation of germline
findings. Approximately one-third of these pedigrees had at
least one feature suggestive of possible inherited risk, and
some participants had a clear indication for clinical genetic
testing. However, the primary purpose of the initial study visit
is discussion of a complex research protocol, not provision of
clinical genetic risk assessment or counseling. To minimize
confusion and maintain a clear boundary between research
and clinical testing, GCs have opted not to broach the topic of
clinical genetic testing during a study visit unless it is specif-
ically raised by a participant. Instead, recommendations for
clinical evaluation and genetic testing are communicated dur-
ing presentation at the PMTB and included in the written
report returned to the referring clinician. There will be missed
opportunities to provide potentially beneficial information to
study participants using this approach. However, we believe
this approach more fully respects participant autonomy and
allows the focus to remain on the complicated study related
discussion and decision making as exemplified in the follow-
ing case.
Participant C enrolled in MI-ONCOSEQ as an adult fol-
lowing diagnosis of a squamous cell carcinoma of the thymus.
Five months before study enrollment, he was referred by his
oncologist for clinical evaluation in the UMCGC, but declined
to schedule an appointment. A full pedigree collected at initial
study visit met Amsterdam I criteria for Lynch syndrome,
including young onset colon cancer in the patient’s mother.
Maternal relatives were known to carry a germline mismatch
repair (MMR) gene mutation. The participant, his mother, and
his maternal aunts and uncles were aware of the diagnosis of
Lynch syndrome, but had not pursued clinical testing for the
known mutation and had also declined genetic counseling
despite recommendations from previous clinicians. In discus-
sion with the GC at the study visit they did not verbalize why
they had not pursued clinical evaluation. Upon enrollment in
MI-ONCOSEQ, the participant opted to receive incidental
findings and a germline MMR gene mutation was confirmed.
This result was returned to the referring oncologist as part of
the research report along with a recommendation for clinical
genetic counseling. The participant and his family members
have had no further contact with the UMCGC.
Participant C did not follow through with clinical genetic
counseling and testing despite awareness of and access to
these services as well as knowledge of his risk. His decision
to receive incidental germline findings was discordant from
previous actions. At-risk relatives in families with known
cancer syndromes often do not pursue testing for a variety of
logistical and personal reasons (Sharaf et al. 2013). There may
also be stages of readiness for acceptance of clinical genetics
services that impact adherence to referral recommendations
(O’Neill et al. 2006). Although the patient did not verbalize
his reasons, he was offered clinical services multiple times and
declined. We have continued to maintain clear separation of
research and clinical genetic counseling for study participants,
recognizing that individuals have a right to make autonomous
decisions about clinical services separate from their decisions
to participate in research.
Conclusion
The primary goal of the MI-ONCOSEQ project has been to
implement WGS for targeted oncology therapy. Recognizing
the broader implications of this testing, the project team in-
cludedGCs in protocol development from conception through
implementation. This allowed for GC input on crucial project
elements, including management of potential incidental
germline findings. As the MI-ONCOSEQ project has
progressed, GCs have participated in re-evaluation and adap-
tation of the protocol, a process requiring intra-team commu-
nication and flexibility. GCs have applied traditional skills
including communicating complex genetic information, edu-
cating and gathering feedback from the community in devel-
opment and implementation of the flexible default consent,
helping participants make informed decisions for incidental
findings, and educating and being a resource for physician
colleagues and other study teammembers. Participation in the
PMTB has strengthened existing relationships with oncolo-
gists and increased our interactions and visibility with special-
ty oncologists who may not typically care for patients with
hereditary cancers (e.g. thoracic, head and neck, sarcoma)
creating new opportunities for education and collaboration.
Our experiences with MI-ONCOSEQ demonstrate that
GCs have important existing skills that can be applied in
multi-disciplinary care teams implementing precision
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oncology, another non-traditional area of practice. Our in-
volvement in a large research project provides multiple op-
portunities to engage with patients and physicians in the
precision oncology setting. While involvement at this level
may not be feasible for clinical GCs, there are aspects of our
experience that could be applied outside of a research context.
Broader use of WGS in oncology treatment decision making
and ACMG recommendations for active interrogation of
germline tissue in tumor-normal dyads suggests that GCs will
have increasing opportunities for involvement in this area
(Bombard et al. 2013). Coping with the data generated from
WGS in both the research and clinical settings will require
GCs to develop and enhance understanding of existing tools
and databases available for variant classification. This will be
an important topic for training programs and continuing edu-
cation to address. We encourage GCs to embrace these oppor-
tunities as a natural extension of their existing skills.
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